ArticleFrontiers in microbiology2016
Altered Outer Membrane Transcriptome Balance with AmpC Overexpression in Carbapenem-Resistant
Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Random Forest Modeling to Predict Small Molecule Accumulation in Gram-Negative Bacteria.ACS infectious diseases · 2026Article
- Whole-genome sequencing revealsMicrobial genomics · 2025Article
- Whole genome sequence-based molecular characterization of blood isolates of carbapenem-resistantMicrobiology spectrum · 2024Article
- Factors associated with non-carbapenemase mediated carbapenem resistance of Gram-negative bacteria: a retrospective case-control study.International microbiology : the official journal of the Spanish Society for Microbiology · 2024Article
- Molecular mechanisms of tigecycline-resistance amongFrontiers in cellular and infection microbiology · 2024Review
- Antibacterial and antibiofilm activities of protocatechualdehyde and its synergy with ampicillin against methicillin-resistantFrontiers in microbiology · 2024Article
- Outer Membrane Porins Contribute to Antimicrobial Resistance in Gram-Negative Bacteria.Microorganisms · 2023Review
- Development of Nanobodies as Theranostic Agents against CMY-2-Like Class C β-Lactamases.Antimicrobial agents and chemotherapy · 2023Article
- Cefazolin and imipenem enhance AmpC expression and resistance in NagZ-dependent manner in Enterobacter cloacae complex.BMC microbiology · 2022Article
- Antimicrobial Resistance in Enterobacterales Recovered from Urinary Tract Infections in France.Pathogens (Basel, Switzerland) · 2022Article
- Neonatal multidrug-resistant gram-negative infection: epidemiology, mechanisms of resistance, and management.Pediatric research · 2022Review
- Molecular characterization of NDM-1-producing carbapenem-resistantFrontiers in cellular and infection microbiology · 2022Article
- Proteomic Charting of Imipenem Adaptive Responses in a Highly Carbapenem Resistant ClinicalAntibiotics (Basel, Switzerland) · 2021Article
- Transcriptome-based design of antisense inhibitors potentiates carbapenem efficacy in CREProceedings of the National Academy of Sciences of the United States of America · 2020Article
- Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.Journal of the Pediatric Infectious Diseases Society · 2020Review
- Evaluation of Resistance Mechanisms in Carbapenem-ResistantInfection and drug resistance · 2020Article
- Elevating NagZ Improves Resistance to β-Lactam Antibiotics via Promoting AmpC β-Lactamase inFrontiers in microbiology · 2020Article
- Antibiotic Resistance Profile, Outer Membrane Proteins, Virulence Factors and Genome Sequence Analysis Reveal Clinical Isolates ofFrontiers in cellular and infection microbiology · 2020Article
- Carbapenem-ResistantInfection and drug resistance · 2020Article
- High Prevalence of Metallo-β-Lactamase-ProducingFrontiers in microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing incidence of multidrug-resistant (MDR) bacteria is an emerging challenge in modern medicine. The utility of carbapenems, considered "last-line" agents in therapy of infections caused by MDR pathogens, is being diminished by the growing incidence of various resistance mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.